CRISPR Therapeutics to present Phase 1b CTX310 data in severe hypertriglyceridemia at AHA 2026

PUBT · 2d ago
CRISPR Therapeutics to present Phase 1b CTX310 data in severe hypertriglyceridemia at AHA 2026
  • CRISPR Therapeutics flagged late-breaking Phase 1b clinical data for CTX310 in severe hypertriglyceridemia for AHA Scientific Sessions 2026.
  • Results have not been presented yet; an oral presentation is scheduled for Nov. 9, 2026 at 8:00 a.m. CST.
  • The company did not disclose outcomes, citing an embargo until the presentation.
  • CTX310 is an in vivo CRISPR/Cas9 liver-editing program targeting ANGPTL3, part of a broader cardiometabolic pipeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080830PRIMZONEFULLFEED9841961) on October 08, 2026, and is solely responsible for the information contained therein.